# HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

> **NCT02569320** · PHASE1 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** HDAC Inhibitor AR-42
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT02569320
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-20
- **Primary completion:** 2020-11-14
- **Final completion:** 2021-03-10
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02569320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02569320, "HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02569320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*